BR112016007727A8 - célula hospedeira, e, método para produzir uma proteína n-glicosilada. - Google Patents

célula hospedeira, e, método para produzir uma proteína n-glicosilada.

Info

Publication number
BR112016007727A8
BR112016007727A8 BR112016007727A BR112016007727A BR112016007727A8 BR 112016007727 A8 BR112016007727 A8 BR 112016007727A8 BR 112016007727 A BR112016007727 A BR 112016007727A BR 112016007727 A BR112016007727 A BR 112016007727A BR 112016007727 A8 BR112016007727 A8 BR 112016007727A8
Authority
BR
Brazil
Prior art keywords
producing
host cell
unglycosylated protein
host cells
protein
Prior art date
Application number
BR112016007727A
Other languages
English (en)
Other versions
BR112016007727A2 (pt
Inventor
Fernandez Fabiana
Kowarik Michael
Wacker Michael
Original Assignee
Glycovaxyn Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycovaxyn Ag filed Critical Glycovaxyn Ag
Publication of BR112016007727A2 publication Critical patent/BR112016007727A2/pt
Publication of BR112016007727A8 publication Critical patent/BR112016007727A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

são descritos aqui métodos para inserir sequências de ácido nucleico em células hospedeiras. também são descritos aqui células hospedeiras geneticamente estáveis compreendendo sequências de ácido nucleico inseridas e métodos para usar tais células hospedeiras na geração de proteínas.
BR112016007727A 2013-10-11 2014-10-13 célula hospedeira, e, método para produzir uma proteína n-glicosilada. BR112016007727A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361889672P 2013-10-11 2013-10-11
PCT/EP2014/071889 WO2015052344A1 (en) 2013-10-11 2014-10-13 Methods of host cell modification

Publications (2)

Publication Number Publication Date
BR112016007727A2 BR112016007727A2 (pt) 2017-09-12
BR112016007727A8 true BR112016007727A8 (pt) 2018-01-30

Family

ID=51726490

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007727A BR112016007727A8 (pt) 2013-10-11 2014-10-13 célula hospedeira, e, método para produzir uma proteína n-glicosilada.

Country Status (13)

Country Link
US (2) US11220676B2 (pt)
EP (1) EP3055416B1 (pt)
JP (1) JP2016533719A (pt)
KR (1) KR20160062169A (pt)
CN (1) CN106062203B (pt)
BR (1) BR112016007727A8 (pt)
CA (1) CA2926523C (pt)
EA (1) EA201690529A1 (pt)
ES (1) ES2778074T3 (pt)
IL (1) IL244791A0 (pt)
MX (1) MX371513B (pt)
SG (1) SG11201602546RA (pt)
WO (1) WO2015052344A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9849169B2 (en) 2013-01-17 2017-12-26 Arsanis Biosciences Gmbh MDR E. coli specific antibody
MX371513B (es) 2013-10-11 2020-01-31 Glaxosmithkline Biologicals Sa Metodos de modificacion de celulas huespedes.
FI3110441T3 (fi) 2014-02-24 2024-05-06 Glaxosmithkline Biologicals Sa Uusi polysakkaridi ja sen käyttöjä
CN106794237B (zh) * 2014-04-17 2022-04-12 葛兰素史密丝克莱恩生物有限公司 经修饰的宿主细胞及其用途
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201712678D0 (en) 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
EP3492482A1 (en) * 2017-11-30 2019-06-05 Vaxxilon AG Vaccine against klebsiella pneumoniae
CN108611306B (zh) * 2018-04-03 2021-05-25 华南农业大学 一种研究慢生根瘤菌的基因功能的方法
CN108531439B (zh) * 2018-04-16 2020-04-07 南京工业大学 一种大肠杆菌基因工程菌及其构建方法与应用
CN108774628B (zh) * 2018-07-02 2022-03-25 南开大学 合成致新生儿脑膜炎大肠杆菌糖蛋白结合疫苗的大肠杆菌工程菌及用途
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
AU2020240075A1 (en) 2019-03-18 2021-10-14 Janssen Pharmaceuticals, Inc. Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
WO2020191082A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
JP2021000041A (ja) * 2019-06-24 2021-01-07 トヨタ自動車株式会社 形質転換補助用プラスミド及びこれを用いた形質転換体の製造方法、並びに形質転換方法
CA3173729A1 (en) * 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
KR102160203B1 (ko) * 2020-06-15 2020-09-25 서울시립대학교 산학협력단 데이노잔틴 고생산능을 갖는 변이 균주의 제조방법 및 온도제어를 이용한 데이노잔틴 대량생산 방법
WO2021259742A1 (en) 2020-06-25 2021-12-30 Glaxosmithkline Biologicals Sa Modified exotoxin a proteins
JP7517002B2 (ja) 2020-09-10 2024-07-17 トヨタ自動車株式会社 形質転換体の製造方法及び形質転換方法
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
PE20231934A1 (es) * 2020-10-27 2023-12-01 Pfizer Composiciones de escherichia coli y metodos de las mismas
JP2022087881A (ja) * 2020-12-02 2022-06-14 トヨタ自動車株式会社 形質転換用プラスミド及びこれを用いた形質転換体の製造方法、並びに形質転換方法
JP2022099381A (ja) * 2020-12-23 2022-07-05 トヨタ自動車株式会社 形質転換補助用プラスミド及びこれを用いた形質転換体の製造方法、並びに形質転換方法
JP2022099419A (ja) * 2020-12-23 2022-07-05 トヨタ自動車株式会社 形質転換用プラスミド及びこれを用いた形質転換体の製造方法、並びに形質転換方法
CN113388596B (zh) * 2021-08-16 2021-12-07 翌圣生物科技(上海)股份有限公司 高保真Pfu DNA聚合酶突变体、其编码DNA及其在NGS中的应用
JP2024139548A (ja) * 2023-03-27 2024-10-09 株式会社豊田中央研究所 遺伝子発現方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2607595C (en) * 2005-05-11 2018-11-27 Eth Zuerich Recombinant n-glycosylated proteins from procaryotic cells
SG10201400320TA (en) * 2008-02-20 2014-05-29 Glycovaxyn Ag Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
GB0915403D0 (en) 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
HUE038456T2 (hu) 2009-11-19 2018-10-29 Glaxosmithkline Biologicals Sa Bioszintetikus rendszer, amely immunogén poliszaccharidokat termel prokarióta sejtekben
HUE037956T2 (hu) * 2010-05-06 2018-09-28 Glaxosmithkline Biologicals Sa Kapszuláris Gram-pozitív bakteriális biokonjugátum vakcinák
CA2847621A1 (en) * 2011-09-06 2013-03-14 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
CA2853338A1 (en) * 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. Methods for increasing n-glycan occupancy and reducing production of hybrid n-glycans in pichia pastoris strains lacking alg3 expression
KR20150054800A (ko) * 2012-09-10 2015-05-20 글리코박신 아게 변형된 항원을 포함하는 생체접합체 및 이의 용도
ES2905107T3 (es) 2012-10-12 2022-04-07 Glaxosmithkline Biologicals Sa Procedimientos de modificación de células hospedadoras
CA3125293A1 (en) * 2012-11-07 2014-05-15 Glaxosmithkline Biologicals Sa Production of recombinant vaccine in e. coli by enzymatic conjugation
MX371513B (es) 2013-10-11 2020-01-31 Glaxosmithkline Biologicals Sa Metodos de modificacion de celulas huespedes.

Also Published As

Publication number Publication date
US20220186196A1 (en) 2022-06-16
BR112016007727A2 (pt) 2017-09-12
SG11201602546RA (en) 2016-04-28
CN106062203A (zh) 2016-10-26
IL244791A0 (en) 2016-04-21
KR20160062169A (ko) 2016-06-01
US11220676B2 (en) 2022-01-11
CA2926523C (en) 2023-09-26
CN106062203B (zh) 2020-08-07
MX371513B (es) 2020-01-31
MX2016004575A (es) 2016-07-12
US20170121691A1 (en) 2017-05-04
EP3055416B1 (en) 2020-01-22
ES2778074T3 (es) 2020-08-07
EP3055416A1 (en) 2016-08-17
CA2926523A1 (en) 2015-04-16
JP2016533719A (ja) 2016-11-04
WO2015052344A1 (en) 2015-04-16
EA201690529A1 (ru) 2016-11-30

Similar Documents

Publication Publication Date Title
BR112016007727A8 (pt) célula hospedeira, e, método para produzir uma proteína n-glicosilada.
MX2015004649A (es) Metodos de modificacion de celulas huesped.
BR112017014031A2 (pt) n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado.
MX2019015505A (es) Metodos, modulos, instrumentos y sistemas de procesamiento de celulas automatizados.
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
CY1125029T1 (el) Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων
EA201992795A1 (ru) Способ получения эукариотических клеток с отредактированной днк и набор, используемый в этом способе
BR112018010429A2 (pt) ácidos nucleicos que se direcionam a ácidos nucleicos engenheirados
BR112012026379A2 (pt) métodos para gerar proteína endogenamente marcada
BR112018004725A2 (pt) método para a produção de oligossacarídeos de leite humano em hospedeiros microbianos com importação/exportação modificada e célula hospedeira microbiana
MX2015017110A (es) Integracion dirigida.
AR122864A2 (es) Variantes de lipasa y polinucleótidos que las codifican
BR112015030972A8 (pt) células sc-beta e composições e métodos para geração das mesmas
MX2019005158A (es) Variantes de glucoamilasa y polinucleotidos que las codifican.
BR112016025519A2 (pt) engenharia genética in vivo com vetores de adenovírus
BR112015022491A2 (pt) variantes de inibidor de tecido de metaloprotease tipo três (timp-3), ácido nucleico isolado, vetor de expressão, célula hospedeira isolada e método para produzir uma muteína de timp-3 recombinante, bem como composição e seu uso
TR201908404T4 (tr) İşlenmiş yüksek afinite insan t hücresi reseptörleri.
UY34227A (es) Acido nucleico recombinante que codifica el gen de la toxina axmi270, vectores, células, plantas y sus métodos de empleo
PE20150336A1 (es) Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn
NZ705742A (en) Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
MX2016014235A (es) Biosintesis microbiana de ergotioneina.
BR112016028512A8 (pt) método de cultivo de uma célula de mamífero e método de produção de uma proteína recombinante
MX2014001383A (es) Colageno 7 y metodos relacionados.
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais
MX363690B (es) Expansión de celulas madre adultas in vitro.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: GLAXOSMITHKLINE BIOLOGICALS SA (BE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.